Page last updated: 2024-10-29

indomethacin and Morbid Obesity

indomethacin has been researched along with Morbid Obesity in 1 studies

Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Raees, A1
Bakhamis, A1
Mohamed-Ali, V1
Bashah, M1
Al-Jaber, M1
Abraham, D1
Clapp, LH1
Orie, NN1

Other Studies

1 other study available for indomethacin and Morbid Obesity

ArticleYear
Altered cyclooxygenase-1 and enhanced thromboxane receptor activities underlie attenuated endothelial dilatory capacity of omental arteries in obesity.
    Life sciences, 2019, Dec-15, Volume: 239

    Topics: Adipose Tissue; Adult; Apamin; Arteries; Celecoxib; Charybdotoxin; Cyclooxygenase 1; Cyclooxygenase

2019